Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial)

BACKGROUND: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with poor prognosis. Up to now, no targeted treatment beyond anti-VEGF therapy has been approved for TNBC and cytotoxic agents remain the mainstay of treatment. Ixazomib is a s...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:BMC Cancer
Main Authors: Rinnerthaler, Gabriel, Gampenrieder, Simon Peter, Petzer, Andreas, Burgstaller, Sonja, Fuchs, David, Rossmann, Dieter, Balic, Marija, Egle, Daniel, Rumpold, Holger, Singer, Christian F., Bartsch, Rupert, Petru, Edgar, Melchardt, Thomas, Ulmer, Hanno, Mlineritsch, Brigitte, Greil, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6220453/
https://ncbi.nlm.nih.gov/pubmed/30400780
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-018-4979-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados